UnitedHealth UNH
- Market cap
- $358.3B
- PE
- 22.8×
- 10y median 22.7×
- Forward PE
- 17.6×
- 10y median 19.4×
- Price to sales
- 0.8×
- EV/EBIT
- 16.8×
- Revenue, 12 months
- $449.7B
- +3% on a year ago
- Net margin
- 3.5%
- Free cash flow yield
- n/m
- Q3 FY26 missing
A Superworth story
UnitedHealth is shrinking to get its profit back, and the price already counts on it
Margins are mending under a returning boss, but sales have stalled and Washington sets the rates
The price more than halved, then won back about half the fall
From its November 2024 high to its August 2025 low, the stock lost about 62%, as new Medicare members cost more than planned and it pulled its forecast. Stephen Hemsley, who ran the company from 2006 to 2017, came back as chief executive to fix it. A second scare came in January 2026, when Washington proposed almost no raise in Medicare rates for 2027. The price is up about 60% from its March low.
The engine that broke was the slice of each dollar it keeps
For most of the last decade, UnitedHealth kept about 8 cents of operating profit from each dollar of revenue. Over four quarters to the end of 2025, that slice roughly halved. Repriced plans and dropped members have pulled it back to about 5 cents, the first real sign the fix is working.
Sales stopped growing this year, on purpose
UnitedHealth is walking away from members and markets that lose money. Its Medicare Advantage plans, the private version of Medicare that insurers run for the government, have about 935,000 fewer seniors than at the end of 2025. So four-quarter sales have gone flat since March, after years of growth near 10% a year.
On reported profit it looks dear, and last winter's clean-up is why
On reported profit the stock costs about 24 times the last four quarters, dearer than about two in three days of the last ten years. Most of that is one quarter: charges at the end of 2025 left reported earnings near zero. Adjusted earnings leave such items out, and on them it is about 20 times.
The fear is that the rebound is borrowed
Quarterly profit rose by about three quarters from a year earlier, but 610 million dollars of it came from bills for earlier periods landing below what was set aside. Washington sets Medicare Advantage rates each year. It first proposed almost no raise for 2027, then settled on about 2.5%. The 2028 proposal is due by early February.
On expected earnings, it costs a little less than its habit
At today's price, consensus adjusted earnings for the next twelve months put UnitedHealth at about 18 times, a little under its own ten-year median. Other big insurers trade nearer 13 times, so it still costs more than its rivals on the same measure. This history is rebuilt with today's estimates before late September.
Analysts already count on the goal, so January has to beat it
Analysts already pencil in about 14% higher adjusted earnings for 2027, inside the company's 13% to 16% long-term goal. The finance chief points to the low end, so an outlook there on January 20 only confirms what the price holds. One in the upper half, with costs in check, would be news. If costs or rates bite, the rebound was the easy part.
What has happened lately
- SEC, UnitedHealth Group reports third quarter 2026 results, raises full-year outlookRevenue of $112.7B and adjusted EPS of $4.69, with the medical care ratio down to 88.4% helped by $610M of favorable reserve development. 2026 adjusted EPS now at least $20.50.
- Reuters via BNN Bloomberg, UnitedHealth raises profit forecast again as turnaround efforts gather paceThe CFO calls the low end of the 13% to 16% long-term growth goal a reasonable 2027 starting point. 935,000 Medicare Advantage members left this year, and an analyst credits Stephen Hemsley's return as CEO.
- CNBC, Trump administration finalizes better-than-feared Medicare Advantage payment rate in boost to health insurersMedicare Advantage plans get an average 2.48% raise for 2027, over $13B, against the 0.09% the government proposed in January.
- STAT, UnitedHealth stock tumbles as CEO resigns, 2025 outlook pulledThe 2025 outlook was suspended because medical costs of many new Medicare Advantage members ran higher than expected. Former CEO Stephen Hemsley, who led it from 2006 to 2017, returned to run it.
Headlines link to the original source.
Brought to you by Superworth
Why a stock is priced where it is, one chart at a time.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $94.4B+14% | $99.8B+9% | $98.9B+6% | $100.8B+9% | $100.8B+7% | $109.6B+10% | $111.6B+13% | $113.2B+12% | $113.2B+12% | $111.7B+2% | $112B+0% | $112.7B−0% | |
| Cost of revenue | $10.2B+23% | $11.1B+18% | $11.3B+16% | $11.8B+26% | $12.5B+22% | $12.4B+12% | $13B+15% | $12.6B+6% | $12.7B+2% | $12.8B+4% | $13.4B+3% | n/a |
| SG&A | $13.3B+3% | $14.1B+3% | $13.2B−5% | $13.3B−4% | $12.5B−6% | $13.6B−3% | $13.8B+5% | $15.2B+15% | $17B+36% | $15.4B+13% | $14.3B+4% | $14.4B−6% |
| $7.7B+12% | $7.9B−2% | $7.9B−2% | $8.7B+2% | $7.8B+1% | $9.1B+15% | $5.2B−35% | $4.3B−50% | $380M−95% | $9B−1% | $8B+55% | $6.6B+52% | |
| Interest expense | $830M+23% | $844M+12% | $985M+19% | $1.1B+29% | $1B+21% | $998M+18% | $1B+4% | $1B−7% | $974M−3% | $955M−4% | $962M−6% | n/a |
| Pre-tax income | $6.9B+10% | $1M−100% | $5.7B−22% | $7.6B−1% | $6.8B−1% | $8.1B+810500% | $4.1B−28% | $3.2B−58% | −$720M | $8B−2% | $7B+71% | $5.5B+71% |
| $1.2B−9% | $1.2B−22% | $1.2B−21% | $1.4B−18% | $1B−15% | $1.6B+34% | $510M−59% | $686M−49% | −$938M | $1.5B−9% | $1.3B+155% | $1.2B+78% | |
| Net income | $5.5B+15% | −$1.4B | $4.2B−23% | $6.1B+4% | $5.5B+2% | $6.3B | $3.4B−19% | $2.3B−61% | $10M−100% | $6.3B−0% | $5.5B+61% | $4.1B+75% |
| $5.83+16% | −$1.53 | $4.54−22% | $6.51+4% | $5.98+3% | $6.85 | $3.74−18% | $2.59−60% | $0.01−100% | $6.90+1% | $6.04+62% | $4.56+76% | |
| 935M−1% | 922M−2% | 928M−1% | 930M−1% | 927M−1% | 918M−0% | 910M−2% | 908M−2% | 910M−2% | 910M−1% | 906M−0% | n/a |
Net income: 12 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
EPS, diluted: Q4 FY08 and Q4 FY16: quarter's net income to common over its shares, to the cent. 12 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
Diluted shares: 6 periods, Q4 FY08 to Q4 FY16: share-days: the 12-month average less the 9-month, weighted by days. 12 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet. Figures from older filings without data tags, and from a results release before its 10-Q, are read from the document's text and checked against it.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q4 FY26 | $112.3B | $109.7B to $115.1B | $2.28 | $2.19 to $2.54 | 16 |
| Q1 FY27 | $113.5B | $110.6B to $116.4B | $8.14 | $6.67 to $8.76 | 12 |
| Q2 FY27 | $115.3B | $112B to $118.5B | $6.92 | $6.66 to $7.17 | 5 |
| Q3 FY27 | $116.5B | $113.2B to $119.7B | $5.32 | $5.12 to $5.51 | 5 |
| Q4 FY27 | $117.6B | $114.3B to $120.9B | $3.07 | $2.96 to $3.18 | 5 |
| Q1 FY28 | $120.2B | $116.8B to $123.5B | $9.13 | $8.79 to $9.46 | 6 |
| Q2 FY28 | $122.2B | $118.8B to $125.6B | $7.95 | $7.66 to $8.24 | 6 |
| Q3 FY28 | $123B | $119.5B to $126.4B | $6.51 | $6.27 to $6.74 | 6 |
Peers
Companies in Medical - Healthcare Plans nearest UnitedHealth's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| UNHUnitedHealth | $356.9B | 22.7× | 22.7× | 17.6× | 0.8× | +3% | 3.5% |
| CVSCVS Health | $113.7B | 23.5× | 16.2× | 10.9× | 0.3× | +7% | 1.2% |
| ELVElevance Health | $89.7B | 18.4× | 17.7× | 15.1× | 0.4× | +6% | 2.5% |
| CICigna | $77.8B | 12.2× | 16.1× | 9.3× | 0.3× | +8% | 2.3% |
| HUMHumana | $49.5B | 39.0× | 20.7× | 33.0× | 0.3× | +18% | 0.9% |
| Peer median | $83.8B | 20.9× | 16.9× | 13.0× | 0.3× | +8% | 1.7% |
Investors who own it
Investors we follow who held UnitedHealth at the end of Jun 30, 2026, from their 13F filings.
- Ruane, Cunniff & GoldfarbRuane, Cunniff & Goldfarb (Sequoia Fund)4.6% of portfoliotrimmed
- Chase ColemanTiger Global Management0.5% of portfoliotrimmed
- Ron BaronBaron Capital0.0% of portfolionew
More on UnitedHealth
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 11Health insurers with the highest profit margins
- #9of 33Healthcare stocks with the highest dividend yields
- #6of 10Health insurers with the lowest EV/EBIT
- #9of 11Health insurers with the lowest price to sales ratio
- #10of 11Health insurers with the fastest revenue growth
Its groups
About
- Chief executive
- Stephen Hemsley, since 2025Returned as CEO in May 2025 after leading from 2006 to 2017. Source
- Industry
- Medical - Healthcare Plans
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .